Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States



    Neptune Technologies & Bioressources Inc. and Salt Lake City based Schiff
    Nutrition International, Inc. entered into a distribution agreement for
    U.S. nationwide distribution of Neptune Krill Oil under the brand name
    Schiff(R) MegaRed(TM)

    LAVAL, QC, Nov. 29 /CNW Telbec/ - Neptune Technologies & Bioressources
Inc. (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has entered into
a distribution agreement with Schiff Nutrition International, Inc. for the
distribution of Neptune Krill Oil under the brand name Schiff(R) MegaRed(TM).
Schiff(R) MegaRed(TM) is expected to become available in the consumer mass
market in the United States with an initial product launch through Costco
planned for January 2008.
    Schiff(R) MegaRed(TM) contains Neptune Krill Oil, NKO(R), a marine oil
extracted from Antarctic Krill, patented for its extraction process, natural
and synthetic composition, and for its use as a medication or cosmeceutical.
NKO(R) safety and health benefits have been demonstrated by clinical studies.
The results of a clinical study on hyperlipidemia (high cholesterol) have
shown that NKO(R) may reduce total cholesterol levels, LDL (bad cholesterol)
and triglycerides, while increasing HDL (good cholesterol). Another clinical
study has shown that NKO(R) can significantly reduce an inflammation biomarker
(CRP) and can improve arthritic symptoms. In order to satisfy the continuously
increasing public demand for safe and effective natural products for
cardiovascular health, Neptune and Schiff Nutrition have joined efforts to
make Schiff(R) MegaRed(TM) readily accessible to the consumer.
    "In line with the company's corporate strategy, Neptune is penetrating
the U.S. dietary supplement mass market in collaboration with Schiff
Nutrition, a leader in its field, recognized for its longstanding consumer
marketing capabilities. As planned, Neptune is increasing consumer awareness
and access to NKO(R) through one of the world's largest retailers, Costco,"
stated Thierry Houillon, Vice-President, Nutraceutical of Neptune. "Schiff
Nutrition's track record and experience in the $22 billion(*) U.S. dietary
supplement market will ensure that a broader portion of the population will
now benefit from our product. Costco operates in 385 U.S. locations and
reported total annual revenues beyond $60 billion and 50.4 million
cardholders. Entering alliances that leverage each partner's marketing and
commercialization network, strength and expertise is part of Neptune's
business strategy," he added.

    About Neptune Technologies & Bioressources Inc.

    Neptune develops proprietary health ingredients from underexploited
marine biomasses, such as krill, with its patented extraction process (Neptune
OceanExtract(TM)). Using its proprietary process, the Company is strategically
positioning itself in the health and wellness market.
    Natural biomass extraction is now playing an important role in developing
nutrigenomics, the next wave in nutritional research. Through strategic
alliances and partnerships, as well as through clinical studies, the Company
continues to demonstrate the beneficial effects of these products. The Company
develops and markets new formulas and new products for specific applications
in high growth markets such as the nutraceutical, cosmeceutical,
biopharmaceutical and nutrigenomics markets.
    Neptune continues to strongly support its strategic development plan to
form partnerships/strategic alliances with worldwide leaders in the
nutraceutical and pharmaceutical industries. Neptune has recently signed
agreements with Nestlé and Yoplait, worldwide leading food manufacturers,
paving its entrance into the global functional food market. According to its
business strategy, negotiations with pharmaceutical companies with the
objective of entering the pharmaceutical market by licensing rights are
ongoing.

    NASDAQ and TSX venture exchange does not accept responsibility for the
    adequacy or accuracy of this press release.

    (*) Business Insights Ltd, 2007

    Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties, and other unknown
factors that could cause the actual results of the Company to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged to
consider statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein are also
subject generally to other risks and uncertainties that are described from
time to time in the Company's reports filed with the Securities and Exchange
Commission.




For further information:

For further information: Toni Rinow, Ph.D., MBA Corporate Development &
Investor Relations, Neptune Technologies & Bioressources Inc., (450) 687-2262,
t.rinow@neptunebiotech.com; www.neptunebiotech.com; Source: Neptune
Technologies & Bioressources Inc.

Organization Profile

Neptune Technologies and Bioressources Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890